
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd is demonstrating strong growth potential driven by its advanced drug candidates, with recent revenue estimates for IMVT-1402 in Graves' Disease being favorably adjusted, indicating a positive trend in revenue forecasts. The company’s drug Brepocitinib has exhibited notable efficacy in rare diseases, particularly dermatomyositis (DM), which is supported by strong Phase 3 VALOR study results that show consistent effectiveness across various manifestations, enhancing investor confidence in its commercial prospects. Additionally, Batoclimab stands out as a unique clinical candidate with disease-modifying potential for Graves' disease, contributing to Roivant's advantageous position in a competitive market.
Bears say
Roivant Sciences Ltd faces challenges stemming from the disappointing outcomes of its clinical trials, particularly the failures of key assets like brepocitinib and IMVT candidates, which undermine the company’s developmental pipeline and prospects for growth. The negative sentiment is compounded by concerns surrounding the potential off-target effects of TSHR antagonism, which raises questions about the safety and efficacy of its drug candidates. Additionally, the reliance on chronic steroid therapies in treated conditions reflects a significant unmet medical need, emphasizing the difficulty Roivant may encounter in establishing competitive and effective treatment solutions in the market.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares